Hypertension in Moderate-to-Severe Nondiabetic CKD Patients

Advances in Chronic Kidney Disease

Volumn 18, Issue 1, 2011, Pages 23-27

  Segura, Julian ^a   Ruilope, Luis M ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Blood pressure; Cardiovascular risk; Chronic kidney disease; Hypertension

Indexed keywords

ALBUMIN;

CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION; PREVALENCE; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; URINALYSIS;

EID: 78651100081     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.11.001     Document Type: Review

References (42)

1. Bakris G.L., Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Clin J Am Soc Nephrol 2009, 4:517-519. World Kidney Day Steering Committee World CKD Day.
2. Kearney P.M., Whelton M., Reynolds K., et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
3. Ruilope L.M., Lahera V., Rodicio J.L., et al. Are renal hemodynamics a key factor in the development and maintenance of arterial hypertension in humans?. Hypertension 1994, 23:3-9.
4. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003, 108:2154-2169.
5. Bakris G.L. Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens 2005, 18(4 Pt 2):112S-119S.
6. Egan B.M., Zhao Y., Axon R.N. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010, 303:2043-2050.
7. Wolf-Maier K., Cooper R.S., Banegas J.R., et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003, 289:2363-2369.
8. Peralta C.A., Hicks L.S., Chertow G.M., et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension 2005, 45:1119-1124.
9. Sarafidis P.A., Li S., Chen S.C., et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med 2008, 121:332-340.
10. Muntner P., Anderson A., Charleston J., et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2010, 55:441-451. Chronic Renal Insufficiency Cohort (CRIC) study investigators.
11. Culleton B.F., Larson M.G., Wilson P.W.F., et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999, 56:2214-2219.
12. Coresh J., Astor B.C., Greene T., et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003, 41:1-12.
13. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
14. Levey A.S., Atkins R., Coresh J., et al. Chronic kidney disease as a global public health problem: approaches and initiatives-a position statement from kidney disease improving global outcomes. Kidney Int 2007, 72:247-259.
15. Segura J., Campo C., Ruilope L.M. How relevant and frequent is the presence of mild renal insufficiency in essential hypertension?. J Clin Hypertens (Greenwich) 2002, 4:332-336.
16. Kendrick J., Chonchol M.B. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 2008, 4:672-681.
17. Coca S.G., Krumholz H.M., Garg A.X., Parikh C.R. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006, 296:1377-1384.
18. Ruilope L.M., Salvetti A., Jamerson K., et al. Renal function and intensive lowering of blood pressure in the hypertensive subjects of the Hypertension Optimal Treatment (HOT) Study. J Am Soc Nephrol 2001, 12:218-225.
19. Rahman M., Pressel S., Davis B.R., et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic. Arch Intern Med 2005, 165:936-946. ALLHAT Collaborative Research Group.
20. Bakris G.L., Sarafidis P.A., Weir M.R., et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375:1173-1181. for the ACCOMPLISH trial investigators.
21. de Leeuw P.W., Ruilope L.M., Palmer C.R., et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004, 164:2459-2464.
22. Mann J.F.E., Gerstein H.C., Pogue J., et al. Renal insufficiency as predictor of cardiovascular outcomes and impact of ramipril: the HOPE randomization trial. Ann Intern Med 2001, 134:629-636.
23. Mann J.F.E., Schmieder R.E., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553. ONTARGET investigators.
24. Ruilope L.M., Zanchetti A., Julius S., et al. Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. J Hypertens 2007, 25:1473-1479. VALUE investigators.
25. Banegas J.R., Segura J., Ruilope L.M., et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004, 43:1338-1344. CLUE study group investigators.
26. Shulman N.B., Ford C.E., Hall W.D., et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. Hypertension 1989, 13(suppl I):I80-I93.
27. Matsushita K., van der Velde M., Astor B.C., et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375:2073-2081. Chronic Kidney Disease Prognosis Consortium.
28. Di Angelantonio E., Chowdhury R., Sarwar N., et al. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ 2010, 341:c4986.
29. Chobanian A., Bakris G.L., Black H.R., et al. The seventh report of the joint National committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
30. Mancia G., De Backer G., Dominiczak A., et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187.
31. Ruilope L.M., van Veldhuisen D.J., Ritz E., et al. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol 2001, 38:1782-1787.
32. Ruilope L.M., Rodicio J.L. Microalbuminuria in clinical practice. Kidney Curr Surv World Lit 1995, 211-216.
33. Brantsma A.H., Bakker S.J., de Zeeuw D., et al. Extended prognostic value of urinary albumin excretion for cardiovascular events. J Am Soc Nephrol 2008, 19:1785-1791. PREVEND Study Group.
34. Warnock D.G., Muntner P., McCullough P.A., et al. Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. Am J Kidney Dis 2010, 56:861-871. REGARDS investigators.
35. Segura J., Ruilope L.M., Rodicio J.L. Microalbuminuria. Clin Exp Hypertens 2004, 26:701-707.
36. Weir M.R. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007, 2:581-590.
37. Freedman B.I., Kopp J.B., Winkler C.A., et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study. Am J Nephrol 2009, 29:626-632.
38. Genovese G., Friedman D.J., Ross M.D., et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010, 13(329):841-845.
39. Kidney Disease Outcomes Quality Initiative (K/DOQI) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43(5 suppl. 1):S1-S290.
40. Mancia G., Laurent S., Agabiti-Rosei E., et al. Reappraisal of European guidelines on hypertension management: a European society hypertension task force document. J Hypertens 2009, 27:2121-2158.
41. Appel L.J., Wright J.T., Greene T., et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010, 363:918-929. AASK collaborative research group.
42. Segura J., Campo C., Rodicio J.L., et al. ACE inhibitors and appearance of renal events in hypertensive nephrosclerosis. Hypertension 2001, 38:645-649.